377 related articles for article (PubMed ID: 33434107)
1. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis.
Kreuter M; Lee JS; Tzouvelekis A; Oldham JM; Molyneaux PL; Weycker D; Atwood M; Kirchgaessler KU; Maher TM
Am J Respir Crit Care Med; 2021 Jul; 204(1):74-81. PubMed ID: 33434107
[No Abstract] [Full Text] [Related]
2. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies.
Behr J; Nathan SD; Costabel U; Albera C; Wuyts WA; Glassberg MK; Haller H; Alvaro G; Gilberg F; Samara K; Lancaster L
Adv Ther; 2023 Sep; 40(9):3937-3955. PubMed ID: 37391667
[TBL] [Abstract][Full Text] [Related]
5. Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis.
Karampitsakos T; Torrisi S; Antoniou K; Manali E; Korbila I; Papaioannou O; Sampsonas F; Katsaras M; Vasarmidi E; Papakosta D; Domvri K; Fouka E; Organtzis I; Daniil Z; Dimeas I; Kirgou P; Gourgoulianis KI; Papanikolaou IC; Markopoulou K; Kounti G; Tsapakidou E; Papadopoulou E; Tatsis K; Gogali A; Kostikas K; Tzilas V; Chrysikos S; Papiris S; Bouros D; Kreuter M; Tzouvelekis A
Respir Res; 2021 May; 22(1):140. PubMed ID: 33952261
[TBL] [Abstract][Full Text] [Related]
6. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study.
Scott MKD; Quinn K; Li Q; Carroll R; Warsinske H; Vallania F; Chen S; Carns MA; Aren K; Sun J; Koloms K; Lee J; Baral J; Kropski J; Zhao H; Herzog E; Martinez FJ; Moore BB; Hinchcliff M; Denny J; Kaminski N; Herazo-Maya JD; Shah NH; Khatri P
Lancet Respir Med; 2019 Jun; 7(6):497-508. PubMed ID: 30935881
[TBL] [Abstract][Full Text] [Related]
7. Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis.
Kreuter M; Lederer DJ; Molina-Molina M; Noth I; Valenzuela C; Frankenstein L; Weycker D; Atwood M; Kirchgaessler KU; Cottin V
Chest; 2019 Oct; 156(4):706-714. PubMed ID: 31047956
[TBL] [Abstract][Full Text] [Related]
8. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis.
Kreuter M; Bonella F; Maher TM; Costabel U; Spagnolo P; Weycker D; Kirchgaessler KU; Kolb M
Thorax; 2017 Feb; 72(2):148-153. PubMed ID: 27708114
[TBL] [Abstract][Full Text] [Related]
9. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Kreuter M; Wuyts W; Renzoni E; Koschel D; Maher TM; Kolb M; Weycker D; Spagnolo P; Kirchgaessler KU; Herth FJ; Costabel U
Lancet Respir Med; 2016 May; 4(5):381-9. PubMed ID: 27050871
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
11. Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss.
Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Yang M; Morgenthien E; Kirchgaessler KU; Cottin V
Respiration; 2022; 101(2):142-154. PubMed ID: 34610600
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
[TBL] [Abstract][Full Text] [Related]
13. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis.
Spagnolo P; Kreuter M; Maher TM; Wuyts W; Bonella F; Corte TJ; Kopf S; Weycker D; Kirchgaessler KU; Ryerson CJ
Respiration; 2018; 96(4):314-322. PubMed ID: 30025392
[TBL] [Abstract][Full Text] [Related]
14. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
15. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
17. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
18. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
19. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
[TBL] [Abstract][Full Text] [Related]
20. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
